Skip to main content

Table 1 Evaluation of the markers using the discovery set with 12 non-lepidic AD and three PDSCC patients

From: Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung

AD markers (Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) AD SCC AD SCC (95 % CI†) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
ST6GALNAC1* 8 0 4 3 0.667 (0.349–0.901) 1.000 (0.292–1.000) 1.000 (0.631–1.000) 0.429 (0.099–0.816) 0.733 (0.099–0.816)
TTF-1 5 0 7 3 0.417 (0.152–0.723) 1.000 (0.292–1.000) 1.000 (0.478–1.000) 0.300 (0.067–0.652) 0.533 (0.266–0.787)
napsin A 2 0 10 3 0.167 (0.021–0.484) 1.000 (0.292–1.000) 1.000 (0.158–1.000) 0.231 (0.050–0.538) 0.333 (0.118–0.616)
SCC markers (Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) SCC AD SCC AD (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
SPATS2* 2 0 1 12 0.667 (0.094–0.992) 1.000 (0.735–1.000) 1.000 (0.158–1.000) 0.923 (0.640–0.998) 0.933 (0.681–0.998)
CK5 1 0 2 12 0.333 (0.008–0.906) 1.000 (0.735–1.000) 1.000 (0.025–1.000) 0.857 (0.572–0.982) 0.867 (0.595–0.983)
DSG3 0 0 3 12 0.000
(0.000–0.708)
1.000
(0.735–1.000)
N.A. 0.800 (0.519–0.957) 0.800 (0.519–0.957)
p40 1 0 2 12 0.333
(0.008–0.906)
1.000
(0.735–1.000)
1.000
(0.025–1.000)
0.857
(0.572–0.982)
0.867 (0.595–0.983)
CK6 0 0 3 12 0.000 (0.000–0.708) 1.000 (0.735–1.000) N.A. 0.800 (0.519–0.957) 0.800 (0.519–0.957)
  1. PPV Positive predictive value, NPV Negative predictive value, 95 % CI 95 % confidence interval, N.A Not available
  2. †:95 % CIs of sensitivity, specificity, PPV, NPV and accuracy were estimated by the Clopper-Pearson method
  3. * Novel biomarkers identified in the present study